Giromed Institute S.L.P. — Clinical Trial Site

19 Registered trials

5 Currently recruiting

Organisation

Giromed Institute S.L.P.

Location

Barcelona, Spain

Identifier

ORG-100048131

Address

Placa Independencia 16 Planta 1 Puerta 2, 17004, Spain

Departments

7010_Pulmonology
GIROMED-CLINICA MI TRES TORRES
Neumología
Neumology
Pectus Respiratory Health
Pneumology
Pneumology service
Pneumonology
Pulmonology
Servicio de Neumologia

Clinical trials at this site (19)

Search interface

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting

2025-521278-32-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2025-12-04
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Recruiting

2022-502570-16-01 Treatment of patients with inadequately controlled mode 4 2024-06-27
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended

2024-519469-23-00 Severe Asthma 4 2025-10-20
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr… Ended

2023-506185-31-00 Idiopathic pulmonary fibrosis (IPF) 10 2024-07-18
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Severe Asthma 4 2024-06-19
A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p… Ended

2023-503333-22-00 Moderate to severe controlled asthma according to Step 5 2024-01-15
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release… Ended

2023-505296-72-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2023-12-12
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler in Patients with Inadequately Controlled Asthma Ended

2024-513568-24-00 Inadequately Controlled Asthma 5 2022-03-23
A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended

2023-505203-23-01 Severe asthma with an eosinophilic phenotype 5 2021-07-26
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Severe and inadequately controlled asthma 5 2021-04-29
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512012-21-00 Chronic Obstructive Pulmonary Disease 5 2021-04-08
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12